Share-based Payment Arrangement, Expense of Longboard Pharmaceuticals, Inc. from 31 Mar 2020 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Longboard Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2024.
  • Longboard Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2024 was $3,376,000, a 294% increase year-over-year.
  • Longboard Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2024 was $8,794,000, a 195% increase year-over-year.
  • Longboard Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,254,000, a 22% increase from 2022.
  • Longboard Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,657,000, a 35% increase from 2021.
  • Longboard Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1,967,000, a 77% decline from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Longboard Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $8,794,000 $3,376,000 +$2,520,000 +294% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $6,274,000 $2,809,000 +$1,968,000 +234% 01 Apr 2024 30 Jun 2024 10-Q 01 Aug 2024 2024 Q2
Q1 2024 $4,306,000 $1,749,000 +$1,052,000 +151% 01 Jan 2024 31 Mar 2024 10-Q 02 May 2024 2024 Q1
Q4 2023 $3,254,000 $860,000 +$268,000 +45% 01 Oct 2023 31 Dec 2023 10-K 12 Mar 2024 2023 FY
Q3 2023 $2,986,000 $856,000 +$61,000 +7.7% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $2,925,000 $841,000 +$142,000 +20% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $2,783,000 $697,000 +$126,000 +22% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $2,657,000 $592,000 +$8,000 +1.4% 01 Oct 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
Q3 2022 $2,649,000 $795,000 +$257,000 +48% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $2,392,000 $699,000 +$187,000 +37% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $2,205,000 $571,000 +$238,000 +71% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $1,967,000 $584,000 -$6,776,000 -92% 01 Oct 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
Q3 2021 $8,743,000 $538,000 +$40,000 +8% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $8,703,000 $512,000 -$43,000 -7.7% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $8,746,000 $333,000 +$238,000 +251% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $8,508,000 $7,360,000 01 Oct 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
Q3 2020 $498,000 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $555,000 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $95,000 03 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1

Longboard Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $3,254,000 +$597,000 +22% 01 Jan 2023 31 Dec 2023 10-K 12 Mar 2024 2023 FY
2022 $2,657,000 +$690,000 +35% 01 Jan 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
2021 $1,967,000 -$6,541,000 -77% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
2020 $8,508,000 03 Jan 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.